Overview

Medtronic is a medical technology company headquartered in Galway, Ireland. Its neuromodulation portfolio includes Intellis and Inceptiv spinal cord stimulation, deep brain stimulation on the Percept system with BrainSense sensing, including adaptive stimulation for Parkinson’s disease, InterStim sacral neuromodulation for bladder and bowel control, and Altaviva, an implantable tibial neuromodulation device approved by the FDA in September 2025.

Deals and partnerships

Medtronic announced on 20 May 2026 that it would acquire SPR Therapeutics, maker of the Sprint 60-day percutaneous peripheral nerve stimulation system for chronic pain, for about $650 million in upfront cash. The deal completed on 16 July 2026. It followed Boston Scientific’s October 2025 agreement to buy Nalu Medical, completed in January 2026, making SPR the second peripheral nerve stimulation specialist bought by a large neuromodulation incumbent in seven months.

In cardiology, Medtronic has partnered with Orchestra BioMed since July 2022 on AVIM Therapy, a blood pressure treatment delivered through standard dual-chamber pacemakers. The BACKBEAT pivotal trial has passed its enrolment target of 316 patients, and Medtronic plans to seek FDA approval if the results are positive. In January 2026 Medtronic and Precision Neuroscience agreed to integrate Precision’s Layer 7 cortical interface with Medtronic’s StealthStation surgical navigation platform.

Why it matters

For neurotechnology companies, Medtronic is both a potential acquirer and a distribution partner. Its recent moves show two routes into the category: buying specialists that already have FDA clearance and commercial uptake, as with SPR, and delivering new software-governed therapies through established implant classes, as with AVIM on standard pacemakers. Whether the Precision collaboration reaches a commercial launch is the signal for brain-computer interfaces.

Coverage on InsideBCI

• 21 May 2026: Medtronic to acquire SPR Therapeutics for $650 million as top-three neuromodulation incumbents consolidate the peripheral nerve stim category
• 27 April 2026: Orchestra BioMed and Medtronic move pacemaker-delivered hypertension therapy toward pivotal readout
• 20 May 2026: BlueWind Medical raises $47.8 million to scale Revi as the implantable tibial neuromodulation category separates from sacral nerve stimulation
• 21 July 2026: Precision Neuroscience demonstrates thought-based gaming in non-paralysed volunteers
• 15 October 2026: CereGate raises Series C for a Parkinson’s walking therapy